{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Antibody Drug Conjugates: New Weapons Against Cancer ((Non-Physician Credit))

Activity Steps

Description

The certificate for this activity is for NON-PHYSICIANS.

Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Purpose of Activity

To provide information on antibody drug conjugates (ADCs) that have been approved by the Food & Drug Administration (FDA).

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Evaluate the use of antibody drug conjugates (ADCs) for patients with advanced/metastatic disease.
  2. Describe the indications for those ADCs that are currently available.
Price: $10.00

Credits:

  • ACCME 1.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Test Code: OTN0320
Published: March 2020
Expires: 3/31/2022
Sources: Oncology Times
Required Passing Score: 7/10 (70%)
Authors: Rebecca Wilson
Categories: Hematology , Oncology
Specialties: Hematology, Oncology
Topics: Cancer , Drug Update